160
s
CIM: What does the future revenue breakdown look like? In other words, what % of revenues will come from research, indoor farming, extraction, drug delivery, and the vertical integrated license facility?
aiso: We believe our technology developments (Growblox, PhytoX, and drug delivery) will be our main revenue producer because this part of our business allows us to go literally everywhere with our technology solutions. Currently, our licensed businesses (cultivation, manufacturing and dispensary operations) are the first ones to provide revenue, but as the market matures, our technology solutions will provide 90% of iaso’s revenue stream.
CIM: How do you plan on solving the problem of consistency, efficacy, and safety in the industry?
aiso: By providing our technology solutions that aim to optimize the output of what we consider to be the four pillars of the process; genetics, cultivation, extraction, and drug delivery. We believe that our technology developments in each of these four segments will significantly improve the consistency, efficacy, and safety of products in the industry.
César Cordero Kruger,
CEO: IASO
Derwin Wallace:: CIM